Literature DB >> 10817673

Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.

C Herrnring1, T Reimer, U Jeschke, J Makovitzky, K Krüger, B Gerber, D Kabelitz, K Friese.   

Abstract

Apoptosis-inducing ligands such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been found to play an important role in cell regulation. Different malignant tumors show an altered expression of these ligands and their respective receptors compared to normal tissues. The purpose of this study was therefore to investigate expression of TRAIL, FasL, and its receptor Fas on protein and mRNA levels in breast carcinomas (n=40), fibroadenomas (n=7), and normal breast tissues (n=5). Immunohistochemical reaction demonstrated that FasL was strongly expressed in breast cancer tissues (34/40) while only one fibroadenoma and one normal breast tissue reacted weakly positive for FasL. All fibroadenomas and normal breast tissues as well as the majority of breast cancer tissues expressed Fas on protein level. Quantitative RT-PCR analysis detected high expression of FasL mRNA in breast cancer tissues and fibroadenomas, whereas fibroadenomas showed the highest Fas mRNA copy numbers, followed by breast cancer tissues and normal breast tissues (P<0.05). Compared to FasL expression, TRAIL could be detected in less breast cancer tissues on protein level (21/40) and was found in only one fibroadenoma and none of the normal breast tissues. Thus, it can be concluded that malignant breast tumors show an altered expression of the two apoptosis-inducing ligands FasL and TRAIL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817673     DOI: 10.1007/s004180050438

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  11 in total

1.  Polymorphisms of the FAS and FASL genes and risk of breast cancer.

Authors:  Wenmin Wang; Zhongqiu Zheng; Wenjie Yu; Hui Lin; Binbin Cui; Feilin Cao
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

2.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.

Authors:  Thomas Kolben; Udo Jeschke; Toralf Reimer; Nora Karsten; Elisa Schmoeckel; Anna Semmlinger; Sven Mahner; Nadia Harbeck; Theresa M Kolben
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

4.  Reversine induces caspase-dependent apoptosis of human osteosarcoma cells through extrinsic and intrinsic apoptotic signaling pathways.

Authors:  Jae-Sung Kim; In-A Cho; Kyeong-Rok Kang; HyangI Lim; Tae-Hyeon Kim; Sun-Kyoung Yu; Heung-Joong Kim; Seul Ah Lee; Sung Min Moon; Hong Sung Chun; Chun Sung Kim; Do Kyung Kim
Journal:  Genes Genomics       Date:  2019-04-05       Impact factor: 1.839

5.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

6.  Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.

Authors:  Ashgan I El-Sarha; Gehan M Magour; Sameh M Zaki; Mohamed Y El-Sammak
Journal:  Pathol Oncol Res       Date:  2008-11-18       Impact factor: 3.201

7.  TRAIL protein expression in breast cancer cells correlates with nuclear grade.

Authors:  Adam Bilski; Grażyna Pasz-Walczak; Robert Kubiak; Piotr Sek; Justyna Chalubinska; Wojciech Fendler; Konrad Wronski; Anna Piekarska; Piotr Pluta; Piotr Potemski; Arkadiusz Jeziorski; Janusz Piekarski
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

8.  Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Authors:  James W Antoon; Rongye Lai; Amanda P Struckhoff; Ashley M Nitschke; Steven Elliott; Elizabeth C Martin; Lyndsay V Rhodes; Nam Seung Yoon; Virgilio A Salvo; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  Sci Rep       Date:  2012-07-27       Impact factor: 4.379

9.  Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.

Authors:  James W Antoon; Ashley M Nitzchke; Elizabeth C Martin; Lyndsay V Rhodes; Seungyoon Nam; Scott Wadsworth; Virgilo A Salvo; Steven Elliott; Bridgette Collins-Burow; Kenneth P Nephew; Matthew E Burow
Journal:  Int J Oncol       Date:  2013-02-08       Impact factor: 5.650

10.  Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.

Authors:  Toralf Reimer; Dirk Koczan; Heiner Müller; Klaus Friese; Hans-Jürgen Thiesen; Bernd Gerber
Journal:  Breast Cancer Res       Date:  2002-06-21       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.